1. Evaluation of Novel Targets, Including CC-Chemokine Receptor 4, in Adult T-Cell Acute Lymphoblastic Leukemia/Lymphoma: A Mayo Clinic Clinical and Pathologic Study
- Author
-
Khurana, Sharad, Heckman, Michael G., Craig, Fiona E., Cochuyt, Jordan J., Greipp, Patricia, Rahman, Zaid Abdel, Sproat, Lisa Z., Litzow, Mark, Foran, James M., and Jiang, Liuyan, "Jennifer"
- Subjects
Immunohistochemistry -- Health aspects ,T cells -- Health aspects ,Leukemia -- Diagnosis ,Antineoplastic agents -- Health aspects ,Antigens -- Health aspects ,Adults -- Health aspects ,Monoclonal antibodies -- Health aspects ,Antimitotic agents -- Health aspects ,Health - Abstract
Context.--Unlike B-cell acute lymphoblastic leukemia/lymphoma (ALL/LBL), there have been few therapeutic advances in T-cell ALL (T-ALL)/LBL, an aggressive ALL/LBL subtype. Objective.--To perform a focused tissue array study to elucidate tumor markers of therapeutic potential in T-ALL/LBL. Design.--Using immunohistochemistry, we evaluated expression of leukemic antigens of interest, specifically CC-chemokine receptor 4 (CCR4), among others, on available remnant diagnostic material, including tumor tissue slides obtained from formalin-fixed, paraffin-embedded preserved tissues. Results.--Our analysis identified, for the first time, expression of CCR4 in T-ALL/LBL in 11 of 27 cases (40.7%) and confirmed common expression of BCL2, CD38, and CD47, as reported previously. We also identified the expression of CD123 in 4 of 26 cases (15.4%), whereas BCL6 and PDL1 were expressed in a small number of T-ALL/LBL cases. The potential novel target CCR4 was significantly more common in the Pre/Pro-T immunophenotypic subtype, 6 of 9 (66.7%, P = .01). No additional differences in clinical and epidemiologic variables were noted among positive or negative CCR4 cases. Conclusions.--These findings support preclinical and clinical testing of therapies targeting CCR4, CD47, BCL2, CD38, and CD123 in T-ALL/LBL, and may help guide the development of targeted clinical trials in T-ALL/LBL, a rare disease in urgent need of novel therapies. doi: 10.5858/arpa.2022-0482-OA, Advances in chemotherapy regimens have remarkably prolonged survival in childhood T-cell acute lymphoblastic leukemia (T-cell ALL [T-ALL]/lymphoblastic lymphoma [LBL]) and recently for younger adults with the adoption of pediatric-inspired regimens. [...]
- Published
- 2024
- Full Text
- View/download PDF